Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

Triple-negative breast cancer (TNBC) remains the poorest-prognosis breast cancer (BC) subtype. Gene expression profiling has identified at least six different triple-negative subtypes with different biology and sensitivity to therapies. The heterogeneous nature of TN tumors may justify the difficult...

Descripción completa

Detalles Bibliográficos
Autores principales: Omarini, Claudia, Guaitoli, Giorgia, Pipitone, Stefania, Moscetti, Luca, Cortesi, Laura, Cascinu, Stefano, Piacentini, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772398/
https://www.ncbi.nlm.nih.gov/pubmed/29391830
http://dx.doi.org/10.2147/CMAR.S146658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772398/
https://www.ncbi.nlm.nih.gov/pubmed/29391830
http://dx.doi.org/10.2147/CMAR.S146658

Ejemplares similares